# OnCo record vusolimogene-oderparepvec (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/vusolimogene-oderparepvec/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "vusolimogene-oderparepvec" ;
  schema:name "Vusolimogene oderparepvec"@en ;
  schema:description "Vusolimogene oderparepvec is an engineered herpes virus injected into melanoma tumours, approved in August 2026 with nivolumab after immunotherapy failure."@en ;
  schema:url <https://onco.cc/drugs/vusolimogene-oderparepvec/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Vusolimogene%20oderparepvec> ;
  onco:status "approved" ;
  onco:modality "Oncolytic virus (HSV-1)" ;
  schema:alternateName "Tudriqev" ;
  onco:approval "US 2026: Unresectable/metastatic melanoma after anti-PD-1, with nivolumab (accelerated)" ;
  onco:acceleratedApproval "US 2026-08-06: In combination with nivolumab for treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression with a programmed death receptor-1 (PD-1)-blocking antibody-based regimen" ;
  onco:cancers <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/advanced-melanoma/> ;
  onco:technologies <https://onco.cc/technologies/oncolytic-virus/> ;
  onco:drugs <https://onco.cc/drugs/nivolumab/> ;
  onco:companies <https://onco.cc/companies/replimune/>, <https://onco.cc/companies/bms/> ;
  onco:trials <https://onco.cc/trials/nct06264180/>, <https://onco.cc/trials/nct06898970/> .